Document:

atra-ex101_176.htm

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND is the type that the registrant treats as private or confidential.

Exhibit 10.1

DEED OF AMENDMENT NUMBER 1

TO

THIRD AMENDED AND RESTATED LICENSE AGREEMENT

 

 

This Deed of Amendment Number 1 to the Third Amended and Restated License Agreement (“Amendment #1”), effective as of April 21, 2021 (“First Amendment Effective Date”), amending the Third Amended and Restated Research and Development Collaboration Agreement (“Agreement”) entered into on August 26, 2020, is made by and between Atara Biotherapeutics, Inc., having its principal offices at 611 Gateway Blvd #900, South San Francisco, California 94080, U.S.A. (“Atara”), and the Council of the Queensland Institute of Medical Research, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”). Each of Atara and Institute are referred to in this Amendment #1 as a “Party”, and collectively as the “Parties”.

 

WHEREAS, for the [***], the Parties have agreed to research and develop T cells comprising engineered T-cell receptors [***]; and

 

WHEREAS, the Parties desire to amend the terms of the Agreement and to, among other things, [***].

 

NOW, THEREFORE, Institute and Atara hereby agree to the following terms and conditions in this Amendment.

 

	
1.
	
DEFINED TERMS

 

Except as otherwise defined herein, capitalized terms in this Amendment #1 will have the same meaning as set forth in the Work Order and the Agreement.

 

	
2.
	
AMENDMENTS

 

	
 
	
a.
	
References to [***] in the Agreement shall be deleted in their entirety and replaced with [***]

 

	
 
	
b.
	
Section 1.45 is hereby deleted in its entirety and replaced as follows:

 

“1.45 “HPV-Specific [***] Product” means a pharmaceutical or biologic product comprising [***], Specifically Directed to one or more Targets associated with human papilloma virus (“HPV”), including [***] associated with HPV or [***]  with HPV.”

 

All references to “HPV-Specific [***] Product” now refers to “HPV-Specific [***] Product”.

	
 
	
c.
	
Section 4.8(a)(iii) is hereby deleted in its entirety and replaced as follows:

 

“(iii) (A) the tenth (10th) anniversary of the First Commercial Sale of such Licensed Product (other than an HPV-Specific [***] Product) in such country; and (B) for an HPV-Specific [***] Product, the twelfth (12th) anniversary of the First Commercial Sale of such HPV-Specific [***] Product (the “Royalty Term”).”

 

	
 
	
d.
	
Section 5.1(b) is hereby deleted in its entirety and replaced as follows:

 

“(b)[***]; and”

 

Except as otherwise set forth in this Amendment #1, the Agreement shall otherwise continue in full force and effect in accordance with its terms.  Nothing in this Amendment #1 prejudices or adversely affects any right, power, authority, discretion or remedy arising under the Agreement before the First Amendment Effective Date, or discharges, releases or otherwise affects any liability or obligation arising under the Agreement before the First Amendment Effective Date.

 

	
3.
	
APPLICABLE LAW

 

This Amendment #1 shall be governed by the laws of the State of New York without regard to the conflict of law principles thereof. Any disputes arising hereunder shall be adjudicated accordance with Article 14 of the Agreement.

 

	
4.
	
CONSTRUCTION

 

Except where the context otherwise requires, wherever used, the use of any gender will be applicable to all genders, and the word "or" is used in the inclusive sense. When used in this Amendment #1, “including” means “including without limitation”. References to either Party include the successors and permitted assigns of that Party. The Recitals are incorporated by reference into this Amendment #1. The headings of this Amendment #1 are for convenience of reference only and in no way define, describe, extend or limit the scope or intent of this Amendment #1 or the intent of any provision contained in this Amendment #1. The Parties have each consulted counsel of their choice regarding this Amendment #1, and, accordingly, no provisions of this Amendment #1 will be construed against either Party on the basis that the Party drafted this Amendment #1 or any provision thereof. The official text of this Amendment #1, any notice given or accounts or statements required by this Amendment #1, and any dispute proceeding related to or arising hereunder, will be in English. If any dispute concerning the construction or meaning of this Amendment #1 arises, then reference will be made only to this Amendment #1 as written in English and not to any translation into any other language.

 

	
5.
	
COUNTERPARTS

 

This Amendment #1 may be executed in one or more counterparts, each of which together shall constitute one and the same agreement. For purposes of executing this Amendment #1, a facsimile (including a PDF image delivered via email) copy of this Amendment #1, including the signature pages, will be deemed an original. The Parties agree that neither Party will have any rights to challenge the use or authenticity of a counterpart of this Amendment #1 based solely on the grounds that its signature, or the signature of the other Party, on  such counterpart is not an original signature.

 

 

[Signature Page Follows]

 

 

IN WITNESS WHEREOF, the undersigned have entered into this Amendment #1 as of the date first set forth above.

 

 

Agreed and Accepted By:

 

	
Atara Biotherapeutics, Inc.

	
 
	
 
	
 

	
 
	
 
	
 

	
By:  
	
/s/ [***]
	
 

	
 
	
 
	
 

	
Name:
	
[***]
	
 

	
 
	
 
	
 

	
Title:
	
Head of R&D
	
 

	
 
	
 
	
 

	
 
	
 
	
 

	
 
	
 
	
 

	
Council of the Queensland Institute of Medical Research

	
 
	
 
	
 

	
 
	
 
	
 

	
By:  
	
/s/ [***]
	
 

	
 
	
 
	
 

	
Name:
	
[***]
	
 

	
 
	
 
	
 

	
Title:
	
Acting Chief Operating OfficerDocument

Exhibit 10.1

THIS THIRD AMENDMENT TO THE FULTON FINANCIAL CORPORATION DEFERRED COMPENSATION PLAN, as restated December 1, 2015, is hereby adopted and effective, as set forth below.

WITNESSETH:

            WHEREAS, Fulton Financial Corporation (herein called the “Principal Employer”), along with various of its subsidiaries, heretofore adopted a nonqualified deferred compensation plan for the benefit of eligible employees known as the Fulton Financial Corporation Deferred Compensation Plan (the “Plan”);

            WHEREAS, Section 6.02 of the Plan provides that the Principal Employer has the right to amend the Plan through its Retirement Plans Administrative Committee (the “Committee”) if the Committee determines the amendment is helpful to the administration and operation of the Plan and is not expected to have a material financial impact on the liability of the Employers under the Plan; and

            WHEREAS, the Principal Employer desires to amend the Plan to clarify that no domestic relations order will be applied to any Participant’s account under the Plan;
            NOW, THEREFORE, by virtue and in exercise of the amending power reserved to the Committee by Section 6.02 of the Plan, the Plan is hereby amended, effective March 11, 2021, as follows:

1.         Section 6.04 of the Plan is amended to add two new sentences to the end thereof, to read as follows:

For the avoidance of doubt, no portion of a Participant’s Account balance may be paid to another person under the terms of any domestic relations order issued pursuant to a State's domestic relations law (a “Domestic Relations Order”).  Further, no Domestic Relations Order shall apply to divide, or change the payment timing of, any Account under the Plan.

IN WITNESS WHEREOF, this Third Amendment was duly executed on this 26th day of March, 2021.
                                                                        FULTON FINANCIAL CORPORATION
                                                                        RETIREMENT PLANS 
                                                                        ADMINISTRATIVE COMMITTEE
                                                                        By:      /s/ Bernadette M. Taylor                     
Bernadette M. Taylor
Senior Executive Vice President and
Chief Human Resources OfficerDocument

Exhibit 10.2

THIS FOURTH AMENDMENT TO THE FULTON FINANCIAL CORPORATION DEFERRED COMPENSATION PLAN, as restated December 1, 2015, is hereby adopted and effective, as set forth below.

WITNESSETH:

            WHEREAS, Fulton Financial Corporation (herein called the “Principal Employer”), along with various of its subsidiaries, heretofore adopted a nonqualified deferred compensation plan for the benefit of eligible employees known as the Fulton Financial Corporation Deferred Compensation Plan (the “Plan”);

            WHEREAS, Section 6.02 of the Plan provides that the Principal Employer has the right to amend the Plan through its Board of Directors (the “Board”);

            WHEREAS, the Principal Employer desires to amend the Plan to clarify its delegation to the Retirement Plans Administrative Committee of the Principal Employer the authority and responsibilities of administering the Plan; and

WHEREAS, the Principal Employer desires to amend the Plan to delegate to the Human Resources Committee of the Board the authority to amend the Plan in accordance with Sections 6.02(a) and 6.02(b) of the Plan;

            NOW, THEREFORE, by virtue and in exercise of the amending power reserved to the Principal Employer by Section 6.02 of the Plan, the Plan is hereby amended, effective July 20, 2021, as follows:

1.         Section 1.02 of the Plan is amended to read, in its entirety, as follows:

Fulton Financial Corporation.  Fulton Financial Corporation has delegated responsibility for the administration of the Plan to the Retirement Plans Administrative Committee of the Principal Employer (the “Committee”). 

2.         Section 6.02 of the Plan is amended to read, in its entirety, as follows:

Fulton Financial Corporation shall have the right to amend the Plan at such time or times and in such manner as it deems advisable and, by adopting this Plan, each Employer is deemed to consent to, and be bound by, any such amendment without further act or deed.  Notwithstanding the foregoing, no amendment shall affect the amount of the Participant’s accrued but unpaid benefit (including the amount of the deemed earnings that have accrued thereon), or the right of the Participant to receive his accrued but unpaid benefit, at the time the amendment becomes effective.

(a)        Any such amendment shall be adopted by resolution of either the board of directors of Fulton Financial Corporation, or the Human Resources Committee of the board of directors of Fulton Financial Corporation (the “Human Resources Committee”), and shall be executed by an officer authorized to act on behalf of Fulton Financial Corporation.  A copy of the amendment shall be delivered to the Administrator and each Employer.

(b)        In addition, the Committee also shall have the right to amend the Plan at any time and from time to time with respect to any one or more of the following:
(1)        Amendments required by relevant law, regulation or ruling;

(2)        Amendments that can reasonably be characterized as technical or ministerial in nature; and

(3)        Other amendments helpful to the administration and operation of the Plan as determined by the Committee in its sole discretion provided that such amendments are not expected to have a material financial impact on the liability of the Employers under the Plan.

Notwithstanding the foregoing, the Committee shall not have the power to make an amendment to the Plan that could reasonably be expected to result in the termination of the Plan, a change in the powers, duties or responsibilities of the Administrator, or any increase in the duties or responsibilities of any Employer, unless such amendment is approved or ratified by either the board of directors of Fulton Financial Corporation, or the Human Resources Committee.   

IN WITNESS WHEREOF, this Fourth Amendment was duly executed on this 20th day of July, 2021.

                                                                        FULTON FINANCIAL CORPORATION

                                                                        By:      /s/ Bernadette M. Taylor                     
Bernadette M. Taylor
Senior Executive Vice President and
Chief Human Resources Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]